Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Agriflu vs Fluvirin in Healthy Adults Aged 50+
NCT01867021Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2013
- Primary completion
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial of agriflu in influenza (2 arms), sponsored by Novartis. Primary endpoints: Hemagglutination Inhibition Geometric Mean Titers at Day 22 and Percentages of Subjects Achieving Seroconversion in Antibody Titers at Day 22. Started May 2013; status: completed.
02
Drugs
agriflu
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01867021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01867021.